Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Sierra Oncology, Inc. (DNAI)
since 2015 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Sierra Oncology, Inc..
Table 2 shows the detailed insider transactions.
This company's CIK number is 1290149.
Total stock buying since 2015: $86,685,412.
Total stock sales since 2015: $1,144,957.
Total stock option exercises since 2015: $304,982.
Table 3. Detailed insider trading at Sierra Oncology, Inc. (DNAI)
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2022-04-06 | Turner William D. (Chief Reg & Tech Ops Officer) | Sale | 6,347 | 37.25 | 236,406 |
| 2022-04-06 | Turner William D. (Chief Reg & Tech Ops Officer) | Option Ex | 6,347 | 12.05 | 76,481 |
| 2022-04-05 | Turner William D. (Chief Reg & Tech Ops Officer) | Sale | 100 | 37.09 | 3,709 |
| 2022-04-05 | Turner William D. (Chief Reg & Tech Ops Officer) | Option Ex | 100 | 12.05 | 1,205 |
| 2022-04-04 | Thomson Mary Christina (General Counsel, CCO & Sec'y) | Sale | 2,000 | 35.14 | 70,276 |
| 2022-04-04 | Thomson Mary Christina (General Counsel, CCO & Sec'y) | Option Ex | 2,000 | 13.04 | 26,080 |
| 2022-03-18 | Turner William D. (Chief Reg & Tech Ops Officer) | Sale | 100 | 37.05 | 3,704 |
| 2022-03-18 | Turner William D. (Chief Reg & Tech Ops Officer) | Option Ex | 100 | 12.05 | 1,205 |
| 2022-03-17 | Turner William D. (Chief Reg & Tech Ops Officer) | Sale | 3,453 | 37.06 | 127,954 |
| 2022-03-17 | Turner William D. (Chief Reg & Tech Ops Officer) | Option Ex | 3,453 | 12.05 | 41,608 |
| 2022-03-04 | Thomson Mary Christina (General Counsel, CCO & Sec'y) | Sale | 2,000 | 30.60 | 61,196 |
| 2022-03-04 | Thomson Mary Christina (General Counsel, CCO & Sec'y) | Option Ex | 2,000 | 13.04 | 26,080 |
| 2022-02-04 | Thomson Mary Christina (General Counsel, CCO & Sec'y) | Sale | 2,000 | 29.78 | 59,560 |
| 2022-02-04 | Thomson Mary Christina (General Counsel, CCO & Sec'y) | Option Ex | 2,000 | 13.04 | 26,080 |
| 2022-02-02 | Longitude Prime Fund, L.p. (10% Owner) | Buy | 175,000 | 27.00 | 4,725,000 |
| 2022-02-02 | Richardson Joshua (Director) | Buy | 175,000 | 27.00 | 4,725,000 |
| 2022-01-31 | Sinclair Andrew | Buy | 150,000 | 27.00 | 4,050,000 |
| 2022-01-31 | Aggarwal Gaurav (Director) | Buy | 800,000 | 27.00 | 21,600,000 |
| 2022-01-31 | Vivo Ventures Vii Affiliates Fund, L.p. | Buy | 800,000 | 27.00 | 21,600,000 |
| 2022-01-31 | Abingworth Llp | Buy | 150,000 | 27.00 | 4,050,000 |
| 2022-01-26 | Turner William D. (Chief Reg & Tech Ops Officer) | Sale | 5,000 | 27.05 | 135,250 |
| 2022-01-26 | Turner William D. (Chief Reg & Tech Ops Officer) | Option Ex | 5,000 | 12.05 | 60,250 |
| 2022-01-26 | Thomson Mary Christina (General Counsel & Secretary) | Sale | 2,000 | 29.00 | 58,000 |
| 2022-01-26 | Thomson Mary Christina (General Counsel & Secretary) | Option Ex | 2,000 | 13.04 | 26,080 |
| 2021-11-24 | Collard Craig A (Director) | Buy | 7,899 | 23.09 | 182,348 |
| 2021-11-23 | Collard Craig A (Director) | Buy | 5,601 | 22.95 | 128,514 |
| 2021-05-19 | Dilly Stephen George (CEO and President) | Buy | 5,000 | 17.83 | 89,149 |
| 2020-08-18 | Klencke Barbara (Chief Development Officer) | Buy | 9,275 | 12.24 | 113,488 |
| 2019-08-23 | Klencke Barbara (Chief Development Officer) | Buy | 108,000 | .44 | 47,412 |
| 2019-08-22 | Klencke Barbara (Chief Development Officer) | Buy | 121,000 | .44 | 53,361 |
| 2018-12-10 | Allen Andrew R (Director) | Buy | 66,000 | 1.64 | 108,240 |
| 2017-03-08 | You Angie (Chief Bus. & Strat. Officer) | Buy | 30,000 | 1.43 | 42,900 |
| 2017-02-14 | Topper James N (Director) | Buy | 5,925,926 | 1.35 | 8,000,000 |
| 2016-03-22 | Chapman Wendy (SVP Clinical Operations) | Sale | 3,000 | 7.01 | 21,024 |
| 2016-03-22 | Chapman Wendy (SVP Clinical Operations) | Option Ex | 3,000 | .97 | 2,907 |
| 2016-01-22 | Rodigueza Wendi (Chief Scientific Officer) | Sale | 1,000 | 9.66 | 9,660 |
| 2016-01-22 | Chapman Wendy (SVP Clinical Operations) | Sale | 5,000 | 9.39 | 46,975 |
| 2016-01-22 | Chapman Wendy (SVP Clinical Operations) | Option Ex | 5,000 | .97 | 4,845 |
| 2016-01-21 | Rodigueza Wendi (Chief Scientific Officer) | Sale | 1,000 | 10.32 | 10,323 |
| 2016-01-20 | Rodigueza Wendi (Chief Scientific Officer) | Sale | 1,000 | 9.59 | 9,590 |
| 2016-01-15 | Glover Nicholas (CEO and President) | Sale | 5,000 | 10.04 | 50,225 |
| 2016-01-15 | Glover Nicholas (CEO and President) | Option Ex | 5,000 | .97 | 4,845 |
| 2016-01-12 | Lovejoy Chandra D (SVP of Reg. Affairs & Quality) | Sale | 20,973 | 11.50 | 241,105 |
| 2016-01-12 | Lovejoy Chandra D (SVP of Reg. Affairs & Quality) | Option Ex | 7,551 | .97 | 7,316 |
| 2015-07-21 | Orbimed Private Investments V, Lp (Director) | Buy | 175,000 | 17.00 | 2,975,000 |
| 2015-07-21 | Vivo Ventures Vii Affiliates Fund, L.p. (Other) | Buy | 220,000 | 17.00 | 3,740,000 |
| 2015-07-21 | Cha Albert (Director) | Buy | 220,000 | 17.00 | 3,740,000 |
| 2015-07-21 | Thompson Peter A. (Director) | Buy | 175,000 | 17.00 | 2,975,000 |
| 2015-07-21 | Topper James N (Director) | Buy | 220,000 | 17.00 | 3,740,000 |
Insider trading activities including stock purchases, stock sales, and option exercises
of DNAI listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Sierra Oncology, Inc. (symbol DNAI,
CIK number 1290149) see
the Securities and Exchange Commission (SEC) website.